Evaluation of Serum Levels of Interlukin-15 and Interlukin-21 in Patients With Alopecia Areata
NCT05910138 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2023-06-22
Summary
Alopecia areata (AA) is a type of non-cicatricial alopecia. The most common presentation of AA is localized patches of hair loss on the scalp. The extensive forms of AA presented as diffuse hair loss of the scalp (alopecia totalis) and diffuse hair loss through the entire body including the eyelashes and eyebrows (alopecia universalis).
AA affects approximately 2% of the general population. AA occurs at any age. The peak of incidence is higher in the second and third decades of life.
AA may be associated with several autoimmune diseases including thyroid diseases, lupus erythematosus, vitiligo, psoriasis, rheumatoid arthritis and inflammatory bowel disease. The frequency of the disease varies between geographically separate populations. These diseases associations suggest a relationship between AA and autoimmunity.
Human hair has an important cosmetic and communicational role. We may find significant psychological distress in persons with partial and complete hair loss. AA is associated with psychiatric morbidity especially anxiety and depression.
The pathogenesis of AA involves a complex interaction between genetic, environmental and immune factors. The histopathology of the disease differs according to the stage of the disease. In the acute stage of AA, there is a dense accumulation of lymphocytes (CD4 \&CD8) around hair bulbs so called swarm of bees. In chronic stage, the inflammation may or may not resolve, but there is increase in number of catagen and, or telogen hair and pigmentary incontinence. In the recovery stage, there is minimal inflammation and increase in anagen hair.
T-helper17 cells are unique subset of T-helper cells which produce many interleukins (IL) e.g. IL-17A, IL-17F, IL-21, IL-22, IL-6 and tumor necrosis factor (TNF). The maturation of Th-17 needs the stimulation of naïve T cells by both TGF and IL-21. IL-21 is a cytokine that is produced mostly by activated CD4 T cells. It controls the differentiation and activity of T cells, B cells and NK cells. IL-21 could be a promising marker in the diagnosis of AA and also can be used as a marker of its activity.
IL-15 is a pleotropic cytokine that has multiple effects on different body cell types. It affects the function of cells of both innate and adaptive immune system. IL-15 is well known to promote lymphocytic development and suggested to play a role in some autoimmune diseases e.g. multiple sclerosis, rheumatoid arthritis, ulcerative colitis and celiac disease. IL-15 inhibits the well-known self-tolerance that mediated by activation - induced cell death, promotes maintenance of CD8+ memory T cells with induction of some cytokines which involved in autoimmune process e.g. TNF- and IL-1B. IL-15 is positively correlated with the number and the extent of AA so it could be a possible marker of AA severity.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Serum Interlukin-21
Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
- DIAGNOSTIC_TEST
-
Serum Interlukin-15
Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
Sponsors & Collaborators
-
Sohag University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-01
- Primary Completion
- 2024-07-01
- Completion
- 2024-07-01
Countries
- Egypt
Study Locations
More Related Trials
-
Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata
NCT01559584 ·Status: COMPLETED ·Phase: NA
-
Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation
NCT03473600 ·Status: UNKNOWN ·Phase: PHASE4
-
Combined Microneedling and Topical Pentoxifylline Vesrus Intalesional Pentoxifylline in Treatment of Alopecia Areata: Intra-indiviual Comparative Study
NCT05502952 ·Status: UNKNOWN ·Phase: NA
-
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata
NCT01950780 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients
NCT06562894 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
New Treatment of Alopecia Areata
NCT05594316 ·Status: COMPLETED ·Phase: NA
-
Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata
NCT06088147 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Alefacept in Patients With Severe Scalp Alopecia Areata
NCT00167102 ·Status: COMPLETED ·Phase: NA
-
A Study of Secukinumab for the Treatment of Alopecia Areata
NCT02599129 ·Status: TERMINATED ·Phase: PHASE2
-
Polymorphism of Janus Kinase 1 and 2 (JAK 1&2) in Patients With Alopecia Areata
NCT05861401 ·Status: UNKNOWN ·Phase: NA
-
A Novel Formulation of Sildenafil-loaded Nanocarriers for Treatment of Alopecia Areata
NCT06527729 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
NCT02974868 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
NCT02018042 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacogenomic Study of Androgenetic Alopecia
NCT01227031 ·Status: UNKNOWN
-
A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
NCT07200128 ·Status: COMPLETED
-
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109 ·Status: RECRUITING
-
Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss
NCT06590779 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
NCT03137381 ·Status: COMPLETED ·Phase: PHASE2
-
Quantification of the Socio-economic Multifacet Burden of Alopecia Areata and Identification of the Associated Factors
NCT05588310 ·Status: UNKNOWN
-
Minoxidil Response Testing in Males With Androgenetic Alopecia
NCT02198261 ·Status: COMPLETED
-
A Study of JNJ-64304500 in Participants With Alopecia Areata
NCT04740970 ·Status: WITHDRAWN ·Phase: PHASE2
-
Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata
NCT03535233 ·Status: COMPLETED ·Phase: PHASE4
-
Ocular Finding in Alopecia Areata
NCT03155958 ·Status: UNKNOWN
-
Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
NCT05470413 ·Status: UNKNOWN ·Phase: PHASE3
-
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
NCT04011748 ·Status: UNKNOWN ·Phase: PHASE2